Onconova Therapeutics Future Growth
Future criteria checks 1/6
Onconova Therapeutics's earnings are forecast to decline at 17.4% per annum while its annual revenue is expected to grow at 12% per year. EPS is expected to decline by 3.6% per annum.
Key information
-17.4%
Earnings growth rate
-3.6%
EPS growth rate
Pharmaceuticals earnings growth | 21.4% |
Revenue growth rate | 12.0% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 11 Mar 2024 |
Recent future growth updates
Recent updates
We're Keeping An Eye On Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Rate
Mar 09Here's Why We're Watching Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Situation
Apr 22Onconova Therapeutics (NASDAQ:ONTX) Is In A Good Position To Deliver On Growth Plans
Jul 27Will Onconova Therapeutics (NASDAQ:ONTX) Spend Its Cash Wisely?
Mar 21Companies Like Onconova Therapeutics (NASDAQ:ONTX) Are In A Position To Invest In Growth
Dec 06Onconova Therapeutics names Mark Gelder as chief medical officer
Jun 01Onconova Therapeutics announces $8.7M registered direct offering
Jan 07Onconova cleared to start Phase 1 trial for cancer therapy
Dec 24Onconova Therapeutics EPS in-line, misses on revenue
Nov 12Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 0 | N/A | N/A | N/A | 1 |
12/31/2025 | 0 | -29 | N/A | N/A | 1 |
12/31/2024 | 0 | -24 | N/A | N/A | 2 |
12/31/2023 | 0 | -21 | N/A | N/A | 3 |
9/30/2023 | 0 | -20 | -17 | -17 | N/A |
6/30/2023 | 0 | -21 | -17 | -17 | N/A |
3/31/2023 | 0 | -21 | -17 | -17 | N/A |
12/31/2022 | 0 | -19 | -16 | -16 | N/A |
9/30/2022 | 0 | -17 | -17 | -17 | N/A |
6/30/2022 | 0 | -15 | -17 | -17 | N/A |
3/31/2022 | 0 | -16 | -17 | -17 | N/A |
12/31/2021 | 0 | -16 | -19 | -19 | N/A |
9/30/2021 | 0 | -19 | -21 | -21 | N/A |
6/30/2021 | 0 | -22 | -22 | -22 | N/A |
3/31/2021 | 0 | -25 | -23 | -23 | N/A |
12/31/2020 | 0 | -25 | -23 | -23 | N/A |
9/30/2020 | 0 | -24 | -23 | -23 | N/A |
6/30/2020 | 0 | -23 | -21 | -21 | N/A |
3/31/2020 | 2 | -19 | -21 | -21 | N/A |
12/31/2019 | 2 | -22 | -21 | -21 | N/A |
9/30/2019 | 2 | -21 | -21 | -21 | N/A |
6/30/2019 | 2 | -22 | -24 | -24 | N/A |
3/31/2019 | 1 | -23 | -24 | -24 | N/A |
12/31/2018 | 1 | -21 | -23 | -23 | N/A |
9/30/2018 | 1 | -21 | -22 | -22 | N/A |
6/30/2018 | 1 | -23 | -22 | -22 | N/A |
3/31/2018 | 1 | -21 | -23 | -23 | N/A |
12/31/2017 | 1 | -24 | -24 | -24 | N/A |
9/30/2017 | 1 | -23 | -24 | -24 | N/A |
6/30/2017 | 2 | -18 | N/A | -19 | N/A |
3/31/2017 | 4 | -21 | N/A | -17 | N/A |
12/31/2016 | 6 | -20 | N/A | -16 | N/A |
9/30/2016 | 15 | -11 | N/A | -16 | N/A |
6/30/2016 | 15 | -15 | N/A | -22 | N/A |
3/31/2016 | 13 | -19 | N/A | -26 | N/A |
12/31/2015 | 11 | -24 | N/A | -31 | N/A |
9/30/2015 | 2 | -41 | N/A | -40 | N/A |
6/30/2015 | 0 | -50 | N/A | -46 | N/A |
3/31/2015 | 0 | -57 | N/A | -51 | N/A |
12/31/2014 | 1 | -64 | N/A | -58 | N/A |
9/30/2014 | 3 | -65 | N/A | -61 | N/A |
6/30/2014 | 4 | -71 | N/A | -62 | N/A |
3/31/2014 | 4 | -68 | N/A | -64 | N/A |
12/31/2013 | 5 | -65 | N/A | -61 | N/A |
9/30/2013 | 6 | -62 | N/A | -72 | N/A |
6/30/2013 | 47 | -43 | N/A | -16 | N/A |
3/31/2013 | 47 | -38 | N/A | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ONTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ONTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ONTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ONTX's revenue (12% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: ONTX's revenue (12% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ONTX's Return on Equity is forecast to be high in 3 years time